共 46 条
[1]
Dall TM(2009)Distinguishing the economic costs associated with type 1 and type 2 diabetes Popul Health Manag 12 103-110
[2]
Mann SE(2018)The cost of diabetes care—an elephant in the room Diabetes Care 41 929-932
[3]
Zhang Y(2010)Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial Lancet 376 419-430
[4]
Riddle MC(2018)Cost of achieving HbA1c treatment targets and weight loss responses with once-weekly semaglutide versus dulaglutide in the United States Diabetes Ther 9 951-961
[5]
Herman WH(2018)Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial Diabetes Care 41 258-266
[6]
Ismail-Beigi F(2013)Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States J Manag Care Pharm 19 237-246
[7]
Craven T(2018)Once-weekly semaglutide provides better value for money than a broad range of other type 2 diabetes treatments in Canada: a relative cost of control analysis Can J Diab 42 S41-1589
[8]
Banerji MA(2008)10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 1577-38
[9]
Wilkinson L(2006)Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials Am Heart J 152 27-591
[10]
Hunt B(2008)Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 580-167